Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway

Gemcitabine is the first-line chemotherapeutic agent for pancreatic cancer. However, gemcitabine-resistance frequently leads to poor prognosis. Exploring new chemotherapeutic agents is important for patients with gemcitabine-resistant pancreatic cancer. In this study, we established a new acquired g...

Descripción completa

Detalles Bibliográficos
Autores principales: Weng, Wanwen, Hong, Jiawei, Owusu-Ansah, Kwabena G., Chen, Bingjie, Zheng, Shusen, Jiang, Donghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761725/
https://www.ncbi.nlm.nih.gov/pubmed/36544829
http://dx.doi.org/10.1016/j.heliyon.2022.e12064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761725/
https://www.ncbi.nlm.nih.gov/pubmed/36544829
http://dx.doi.org/10.1016/j.heliyon.2022.e12064

Ejemplares similares